Clinical trial
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma…
NCT00085566 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00085566 |
|---|---|
| Title | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer |
| Official title | A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Prostate Cancer |
| Intervention type | Drug |
| Interventions | everolimus, gefitinib |
| Enrollment | 61 |
| Start date | Mar 1, 2004 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 20, 2016 |
| Countries | Spain, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: